At a glance: BPC-157 is a synthetic 15-amino-acid peptide studied mainly in rats for tendon, muscle and gut injuries. Human evidence is limited to a tiny pilot report and one trial that is still recruiting. It is not FDA-approved, is banned in sport by WADA, and the July 2026 FDA advisory vote in its favor was non-binding.
What is BPC-157?
BPC-157 is a lab-made peptide made of 15 amino acids. "BPC" stands for Body Protection Compound: the sequence was derived from a larger protective protein identified in human gastric juice, and BPC-157 is a short, stable piece of it.
Everything sold today is synthetic. Products may contain the peptide as a free base or as an acetate salt, which are technically different ingredients, one reason product quality varies so much.
How does BPC-157 work?
Researchers have not pinned BPC-157's effects to a single pathway. In lab and animal studies it has been linked to:
- New blood vessel growth (angiogenesis), which brings blood supply to healing tissue
- Fibroblast activity: in tendon-cell studies it changed how the cells that build collagen move, survive and organize
- Growth hormone signaling: in rat tendon cells it increased the number of growth hormone receptors
- The nitric oxide system, which affects blood vessel tone and circulation
These findings come from cells and animals. Whether the same effects happen in people at realistic doses is unknown.
What the research shows so far
BPC-157 is one of the most heavily marketed research peptides and one of the least tested in people.
| Type of study | What was found | Strength of evidence |
|---|---|---|
| Tendon cells and rats (Chang et al., 2011) | Faster tendon outgrowth, better cell survival and migration, improved healing | Lab and animal |
| Animal muscle, ligament and bone injuries | Faster recovery, more blood vessel growth, less inflammation | Animal; mostly one research group |
| Animal gut injuries | Protection against ulcers, inflammatory bowel injury and NSAID damage | Animal |
| Preclinical safety (mice, rats, rabbits, dogs) | No serious toxicity in single- and repeat-dose testing | Animal |
| Pharmacokinetics (rats, dogs) | Measured how the peptide is absorbed and cleared after IV and intramuscular dosing | Animal |
| Human pilot (Lee and Burgess) | Two adults received IV BPC-157 without reported problems | Two people; no control group |
| Phase 2 hamstring trial (NCT07437547) | About 120 adults with acute hamstring strains; BPC-157 plus rehab vs control | Recruiting; no results yet |
Claims about tendon, joint or gut healing in humans are extrapolated from animal data. FDA's 2026 review found very limited clinical information.
Why it gets attention
- Injury recovery: athletes and active people look it up for tendons, ligaments and muscle strains
- Gut health: its gastric origin and animal gut data drive interest for digestive conditions
- Broad animal results across many tissues, which make it sound like a cure-all
- Before-and-after stories online, which can't separate the peptide's effect from rest, rehab or natural healing
How it has been given
In animal studies BPC-157 was given by injection or by mouth. Products sold today come as injectable vials, capsules, oral liquids, nasal sprays and topical forms. Route matters: digestive enzymes can break down a peptide taken by mouth, so experience with one form doesn't describe another. There is no established human route or dose, and this page does not provide dosing guidance.
What about side effects?
Human safety is largely unknown because the studies that would reveal side effects haven't been done. Reported effects include injection-site reactions, nausea, fatigue and lightheadedness. Animal safety testing did not find serious toxicity, but animal results don't transfer reliably to people.
- Blood vessel growth is the most commonly raised theoretical concern, because the same process matters in tumor growth. People with cancer or unexplained growths should discuss this with a doctor.
- Pregnancy and breastfeeding: safety is not established.
- Product quality: strength, purity and sterility vary widely, especially online. FDA has flagged risks of immune reactions and peptide impurities.
Regulatory status
BPC-157 is not an FDA-approved drug for any use. In July 2026 an FDA advisory committee voted 8 to 6, with 1 abstention, to recommend it for the list of substances compounding pharmacies may use. That is often misreported, so precisely:
- The vote is advisory and non-binding. FDA makes the final decision.
- FDA's own scientists recommended against all seven peptides reviewed, finding the studies too short and too small to establish safety or effectiveness.
- Nothing has been added to the list yet. That requires a proposed rule, a public comment period and a final rule, a process that took more than two years the last time.
- It is not an approval and does not make BPC-157 a medicine.
BPC-157 is also on the World Anti-Doping Agency's prohibited list. Athletes subject to testing risk a ban.
BPC-157 and TB-500
BPC-157 is often sold in combination with TB-500, a fragment related to thymosin beta-4, as a "recovery stack." The two have different proposed mechanisms, but no human study has tested them together, so any claimed added benefit is untested. Our TB-500 and BPC-157 + TB-500 pages cover them in detail.
The bottom line
BPC-157 has an unusually broad set of encouraging animal results, which explains its popularity. But human evidence is close to nonexistent, the one real trial has no results yet, and the 2026 advisory vote did not approve it. Until controlled human trials report, claims that it heals injuries in people remain unproven. Anyone dealing with an injury or gut condition should work with a licensed clinician.
Frequently asked questions
What is BPC-157?
A synthetic 15-amino-acid peptide based on a sequence from a protein found in stomach juice. Almost all of the research is in rats and cell cultures.
How is BPC-157 taken?
Injection or oral in animal studies; no established human route.
Is BPC-157 FDA approved?
Not approved; on WADA’s prohibited list.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about BPC-157?
- Healing of tendon, ligament and muscle injuries in rodents.
- Protection of the stomach and gut lining in animal models.
- Blood vessel growth around injuries in lab studies.
What side effects have been reported?
- Unknown in humans — the trials that would reveal side effects have not been done
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. BPC-157 has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011. View source
- Preclinical safety evaluation of BPC 157 in mice, rats, rabbits and dogs. Regulatory Toxicology and Pharmacology. 2020. View source
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology. 2022. View source
- Lee and Burgess. Pilot report of intravenous BPC-157 in two adults. 2025. View source
- ClinicalTrials.gov: BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). View source
- FDA: 2026 evidence and safety review of BPC-157 (Pharmacy Compounding Advisory Committee briefing). View source
- AJMC: FDA panel backs 6 peptides for compounding (July 2026). View source
- Buchanan Ingersoll & Rooney: what the vote means and what comes next. View source
- Rite Aid: BPC-157 overview. View source